A Strano|G Davì - JoVE Visualize

Showing results (11-20 of 133) with videos related to

Pageof 14

Sort By:

Diabetes Research (Edinburgh, Scotland)|January 1, 1989

The relationship of insulin antibodies, platelet-fixing immune complexes and platelet-associated IgG to in vitro platelet aggregation and thromboxane B2 synthesis in childhood type 1 (insulin-dependent) diabetes mellitusG Triolo, G Davì, E Giardina, et al.

Atherosclerosis|September 1, 1989

Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patientsG Davì, M Averna, S Novo, et al.

Cardiologia (Rome, Italy)|January 1, 1989

[Antiplatelet effects of combined therapy with ticlopidine and low doses of aspirin on patients with ischemic cardiopathy]G Davì, I Catalano, A Spatola, et al.

Medical Hypotheses|March 1, 1986

Are the vascular complications of diabetes mellitus preceded by an altered thromboxane/prostacyclin plasmatic ratio?V Tomasi, A Strano, M Orlandi, et al.

Diabetes Research (Edinburgh, Scotland)|January 1, 1989

Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic controlG Davì, M Averna, I Catalano, et al.

Thrombosis Research|June 1, 1982

Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabeticsG Davì, G B Rini, M Averna, et al.

Thrombosis and Haemostasis|August 24, 1982

Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patientsA Strano, G Davì, M Averna, et al.

Prostaglandins, Leukotrienes, and Medicine|March 1, 1983

Plasmatic TXB2 and 6-keto-PGF1 alpha levels during charcoal hemoperfusion in chronic renal failure patientsG Davì, M Orlandi, F Picone, et al.

Haemostasis|January 1, 1982

Enhanced platelet release reaction in insulin-dependent and insulin-independent diabetic patientsG Davì, G B Rini, M Averna, et al.

Cardiologia (Rome, Italy)|December 1, 1989

[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]A Strano, S Novo, A Notarbartolo, et al.

Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:

Pageof 14

Diabetes Research (Edinburgh, Scotland)|January 1, 1989

The relationship of insulin antibodies, platelet-fixing immune complexes and platelet-associated IgG to in vitro platelet aggregation and thromboxane B2 synthesis in childhood type 1 (insulin-dependent) diabetes mellitusG Triolo, G Davì, E Giardina, et al.

Atherosclerosis|September 1, 1989

Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patientsG Davì, M Averna, S Novo, et al.

Cardiologia (Rome, Italy)|January 1, 1989

[Antiplatelet effects of combined therapy with ticlopidine and low doses of aspirin on patients with ischemic cardiopathy]G Davì, I Catalano, A Spatola, et al.

Medical Hypotheses|March 1, 1986

Are the vascular complications of diabetes mellitus preceded by an altered thromboxane/prostacyclin plasmatic ratio?V Tomasi, A Strano, M Orlandi, et al.

Diabetes Research (Edinburgh, Scotland)|January 1, 1989

Platelet function in patients with type 2 diabetes mellitus: the effect of glycaemic controlG Davì, M Averna, I Catalano, et al.

Thrombosis Research|June 1, 1982

Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabeticsG Davì, G B Rini, M Averna, et al.

Thrombosis and Haemostasis|August 24, 1982

Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patientsA Strano, G Davì, M Averna, et al.

Prostaglandins, Leukotrienes, and Medicine|March 1, 1983

Plasmatic TXB2 and 6-keto-PGF1 alpha levels during charcoal hemoperfusion in chronic renal failure patientsG Davì, M Orlandi, F Picone, et al.

Haemostasis|January 1, 1982

Enhanced platelet release reaction in insulin-dependent and insulin-independent diabetic patientsG Davì, G B Rini, M Averna, et al.

Cardiologia (Rome, Italy)|December 1, 1989

[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]A Strano, S Novo, A Notarbartolo, et al.

Pageof 14